Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase I, open-label, multi-centre study designed to assess the safety and tolerability of Cediranib in combination with lomustine in patients with primary recurrent malignant brain tumour.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Cediranib; Lomustine

Criteria

Inclusion Criteria:

• Primary recurrent malignant brain tumour for whom lomustine would be standard therapy
• diagnosis & stage

• Patients received no more than 2 previous systemic chemotherapy regimes

• Life Expectancy > 12 weeks

• Patients must be at least 3 months from the completion of cranial radiation therapy

Exclusion Criteria:

• History of poorly controlled high blood pressure

• Recent major surgery prior to entry into the study